EULAR Highlights 2017

More documents

Recommendations

Info

Friday, June 16, 2017 ORAL PRESENTATIONS From classics to new: synthetic DMARDs in RA Hall 7A – 10:15-11:45 LB0003 OP0230 Tofacitinib With and Without Methotrexate Versus Adalimumab With Methotrexate for the Treatment of Rheumatoid Arthritis: Results From Oral Strategy, A Phase 3b/4 Randomised Trial The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated With Tofacitinib PsA: the options grow! Hall 8 – 10:15-11:45 OP0216 Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients With Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs): A Randomised, Placebo-Controlled, Phase 3 Trial Friday, June 16, 2017 POSTERS FRI0071 FRI0086 Tofacitinib Restores the Inhibition of Reverse Cholesterol Transport Induced by Inflammation: Understanding the Lipid Paradox Associated With Rheumatoid Arthritis Efficacy and Safety Data Based on Historical or Pre-Existing Conditions at Baseline for Patients With Active Rheumatoid Arthritis Who Were Treated With Baricitinib FRI0087 Low Rates of Radiographic Progression of Structural Joint Damage Over 2 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis FRI0089 Effect of Starting Dose of Baricitinib In Achieving Sustained Low Disease Activity FRI0090 Analysis of Neutrophils, Lymphocytes, and Platelets In Pooled Phase 2 and Phase 3 Studies of Baricitinib for Rheumatoid Arthritis FRI0092 Effects of Baricitinib on Haemoglobin and Related Laboratory Parameters in Rheumatoid Arthritis Patients FRI0096 Durability and Maintenance of Efficacy Following Prolonged Treatment With Baricitinib FRI0124 Temporary Interruptions of Study Drug During the Baricitinib Phase 3 Rheumatoid Arthritis Program FRI0231 The First Report of Significant Increase of Body Mass Index in Rheumatoid Arthritis Patients Treated With Tofacitinib During 12-Month Follow-Up FRI0428 The JAK1-Selective Inhibitor, Filgotinib, Inhibits Inflammation Pathways Observed in an IL23-Induced Psoriatic Arthritis Mouse Model FRI0496 Comparing Tofacitinib Safety Profile in Patients With Psoriatic Arthritis in Clinical Studies With Real-World Data FRI0509 Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up To 24 Months in Patients With Active Psoriatic Arthritis: Interim Data From Opal Balance, an Open-Label, Long-Term Extension Study Saturday, June 17, 2017 POSTERS SAT0055 SAT0058 SAT0069 SAT0070 SAT0072 SAT0149 SAT0217 SAT0439 SAT0469 SAT0686 EULAR 2017 Baricitinib Showed Rapid and Greater Reduction in Pain Compared to Adalimumab or Placebo in Patients With Rheumatoid Arthritis Effects of Baricitinib on Patients Who Stop Methotrexate Monotherapy and Switch to Baricitinib Monotherapy A Rapid3-Like Index Documents Superior Efficacy of Baricitinib to Adalimumab and Placebo, Similar To DAS28 And CDAI In The Ra-Beam Clinical Trial In Patients With Rheumatoid Arthritis Baricitinib Versus Adalimumab in Patients With Active Rheumatoid Arthritis: Analysis Of Patients Achieving a Moderate EULAR Response at Week 4 Dose Reduction of Baricitinib in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis Early Patient-Reported Outcomes and Clinical Outcomes With ABT-494 in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate or Tumor Necrosis Factor Inhibitors: Post- Hoc Analysis Of Phase 2 Randomized Controlled Trials Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Active Psoriatic Arthritis Major Adverse Cardiovascular Events: Risk Factors in Patients With RA Treated With Tofacitinib ABSTRACT ONLY AB0098 Effects of Tofacitinib in Early Arthritis Bone Loss AB0235 Effect of Baseline Disease Activity on Achieving Sustained Low Disease Activity in Baricitinib Phase 3 Studies AB0261 Clinical and Structural Responses of Patients With Active Rheumatoid Arthritis (RA) Using Step-Up Dosages of Tofacitinib In A Treat To Target Approach AB0281 Characterization of Changes In Lymphocyte Subsets in Baricitinib- Treated Patients With Early, DMARD Naïve, Rheumatoid Arthritis In A Phase 3 Study AB0403 Adherence and Access to Biological Therapy and Tofacitinib in a Cohort of Colombian Patients With Rheumatological Diseases AB0407 Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy With Tumor Necrosis Factor Inhibitors (TNFi) in Combination With Varying Doses of Methotrexate (MTX) in Patients With Rheumatoid Arthritis AB0419 Real World Use of Tofacitinib in Rheumatoid Arthritis: Data From Latin America AB0431 Post-Marketing Surveillance of Tofacitinib in Japanese Patients With Rheumatoid Arthritis: An Interim Report Of Safety Data AB0432 ABT-494 Has No Effect on the QT Interval at the Doses Being Evaluated in Rheumatoid Arthritis Phase 3 Trials AB0434 Tofacitinib in Rheumatoid Arthritis: Real Life Experience AB0436 Comparison of Tofacitinib Efficacy in Patients With Moderate vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies AB0794 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis: Results from Two Phase 3 Studies Chairman’s picks
Key Presentations – IL-6 Thursday, June 15, 2017 ORAL PRESENTATIONS Progress in biological treatment of RA Hall 8 – 10:15-11:45 OP0102 OP0103 OP0104 OP0105 Patient Reported Benefits of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis The Effect of Sirukumab Plus Methotrexate on Circulating Biomarkers of Joint Destruction in Moderate to Severe Rheumatoid Arthritis Patients from the SIRROUND-D Phase 3 Study Tocilizumab: Dose Reduction or Interval Spacing – Which Proves a Better Tapering Strategy for Rheumatoid Arthritis in Clinical Remission? Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations Heterogeneity in JIA N105/N106 – 13:30-15:00 OP0197 Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis Thursday, June 15, 2017 POSTERS THU0055 THU0130 THU0134 THU0503 THU0511 THU0526 THU0567 Low Molecular Weight BAFF Signaling Inhibitors Ameliorate IL-6, IL-10 and IgG Production In Vitro and In Vivo Models of Autoimmune Diseases Improvement in Measures Of Depressed Mood And Anhedonia in Two Randomized, Placebo-Controlled Phase III Studies Of Sirukumab, A Human Anti-Interleukin-6 Antibody, in Patients With Rheumatoid Arthritis Interstitial Lung Disease and Rheumatoid Arthritis. Multicenter Study With Tocilizumab Identification of Optimal Subcutaneous (SC) Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis (PCJIA) Tocilizumab is a Promising Treatment Option for Therapy Resistent Juvenile Localised Scleroderma Patients Short and Long-Term Follow-Up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Rapid Improvement with Tocilizumab in Refractory and Severe Uveitic Cystoid Macular Edema THU0577 Tocilizumab Monotherapy for Adult Onset Still’s Disease ~ Results of 52- Week Treatment of a Prospective, Single-Center, Single-Arm, Open Trial Friday, June 16, 2017 POSTERS FRI0213 FRI0214 FRI0215 FRI0225 FRI0227 FRI0228 FRI0233 FRI0239 FRI0240 FRI0242 FRI0243 FRI0246 FRI0247 FRI0248 FRI0251 Comparative Effectiveness of Abatacept, Rituximab, Tocilizumab and Anti-TNF Biological DMARDs In RA: Results from the Nationwide Swedish Register Long-Term Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis Despite Anti-Tumor Necrosis Factor Therapy: Results of the Randomized, Phase 3 SIRROUND-T Study Comparative Efficacy and Retention Rate of Tocilizumab and TNF Inhibitors used in Combination With Methotrexate as First-Line Biologic Therapy in Rheumatoid Arthritis: Data from a Multicentre Observational Registry Anemia is a Better Predictor for Radiographic Damage in Rheumatoid Arthritis Than DAS28 When Determined Before Start of Tocilizumab- Treatment – A Secondary Analysis From The ACT-Ray Trial Sarilumab Significantly Suppresses Circulating Biomarkers of Bone Resorption and Cardiovascular Risk Compared With Adalimumab: Biomarker Analysis from the Phase 3 Monarch Study UGT1A1 Genetic Variants Are Associated With Increases In Bilirubin Levels In Rheumatoid Arthritis Patients Treated With Sarilumab The Retention Rates of Abatacept in Elderly RA Patients (65 Years and Above) Who Cannot Be Treated With Methotrexate: Comparison With Etanercept And Tocilizumab; A Single-Center, Retrospective, Case- Control Study Results of a Phase 2b Study of Vobarilizumab, an Anti-Interleukin-6 Receptor Nanobody, as Monotherapy In Patients With Moderate To Severe Rheumatoid Arthritis Rheumatoid Arthritis (RA) Impact Following Treatment With Sarilumab: Patient Reported Outcomes Using The Raid Scale From Two Randomized Phase III Trials Association Between Clinical and Radiographic Responses, and Physical Function in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-To-Severe Rheumatoid Arthritis Sirukumab Treatment Reduces Levels of Iron-Regulatory Proteins and Ameliorates Inflammation-Associated Anemia in Rheumatoid Arthritis Patients Improvements in Health-Related Quality of Life With Sirukumab are Statistically Significant, Clinically Meaningful, and Meet or Exceed Normative Values in Rheumatoid Arthritis Patients with Inadequate Response to Disease-Modifying Antirheumatic Drugs: Post Hoc Analyses of a Phase 3 Trial Median Time to Low Disease Activity is Shorter in Tocilizumab Combination Therapy With csDMARDs as Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to csDMARDs and/or TNF Inhibitors: Subanalysis of the Swiss and Austrian Patients from The ACT-Sure Study Incidence Of Melanoma In Patients With Rheumatoid Arthritis Treated With Tocilizumab Sirukumab, an Anti-Il-6 Cytokine Monoclonal Antibody, Leads to Improvements in Work Productivity and General Health Status in Patients with Active Rheumatoid Arthritis Refractory to Anti-TNF Therapy: Results from the Phase 3 SIRROUND-T Study Chairman’s picks
Page 1 and 2: Enhancing knowledge of the clinical
Page 3: Key Presentations - Cytokine Signal
Page 7 and 8: EULAR 2017 ABSTRACT ONLY AB0051 Int

EULAR Highlights 2017

Create successful ePaper yourself

Delete template?

Save as template?